AstraZeneca Surges on Cancer Drugs | Business and Finance News

AstraZeneca’s Q2 earnings soar with a 5% revenue jump and 2.51B net profit, fueled by blockbuster cancer drugs—plus promising early data on their obesity drug elecoglipron, which could shake up the weight-loss market. Despite a recent trial stumble, CEO remains upbeat, targeting an 80B revenue goal by 2030. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4c8501395046fdc9